Molecular Mechanisms of Malignant Cerebral Edema After LHI (LHI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03703284 |
Recruitment Status :
Recruiting
First Posted : October 11, 2018
Last Update Posted : March 3, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cerebral Edema | Other: Treatments to reduce intracranial pressure |
Study Type : | Observational |
Estimated Enrollment : | 120 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Molecular Mechanisms Underlying the Occurrence of Malignant Cerebral Edema After Large Hemispheric Infarction (LHI) |
Actual Study Start Date : | January 1, 2018 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | June 2023 |
Group/Cohort | Intervention/treatment |
---|---|
LHI Hernia
Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
|
Other: Treatments to reduce intracranial pressure
Drugs such as mannitol, glycerin fructose, etc and/or surgery |
LHI Non-Hernia
Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
|
Other: Treatments to reduce intracranial pressure
Drugs such as mannitol, glycerin fructose, etc and/or surgery |
Healthy control
Healthy individuals
|
- modified Rankin Scale [ Time Frame: 6 months after stroke onset ]modified Rankin Scale: 0 - No symptoms. 1 - No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. A score of 0-4 is considered as a favorable outcome, whereas a score of 5-6 was considered as an unfavorable one. The reasons for death should be also recorded.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 1. 18-80 years old;
- 2. Clinical diagnosis of large hemispheric infarction
- 3. Within 48h after stroke onset.
Exclusion Criteria:
- 1. Clinical diagnosis of severe infection;
- 2. Clinical diagnosis of severe heart, liver or kidney diseases;
- 3. Clinical diagnosis of bleeding tendency, active bleeding or hematological diseases;
- 4. Malignant tumor;
- 5. Modified Rankin Scale (mRS)<2 before stroke onset.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03703284
Contact: Yan Zhang, M.D., PhD | +86 13671376710 | zhangylq@sina.com | |
Contact: Lili Cui, M.D., PhD | +86 13120301056 | samantha47cmu@gmail.com |
China | |
Xuanwu Hospital of Capital Medical University | Recruiting |
Beijing, China, 100053 | |
Contact: Lin-lin Fan, Phd 86-010-83198899 ext 8424 windspring7139@163.com |
Principal Investigator: | Yan Zhang, M.D., PhD | Xuanwu Hospital of Capital Medical University |
Responsible Party: | Yan Zhang, Associate Professor, Xuanwu Hospital, Beijing |
ClinicalTrials.gov Identifier: | NCT03703284 |
Other Study ID Numbers: |
LHI |
First Posted: | October 11, 2018 Key Record Dates |
Last Update Posted: | March 3, 2020 |
Last Verified: | March 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
mechanism, cerebral edema, large hemispheric infarction |
Brain Edema Edema Brain Diseases Central Nervous System Diseases Nervous System Diseases |